Kadmon (NYSE: KDMN) is one of 48 publicly-traded companies in the “Biopharmaceuticals” industry, but how does it compare to its peers? We will compare Kadmon to related businesses based on the strength of its institutional ownership, valuation, profitability, earnings, analyst recommendations, dividends and risk.
This is a summary of recent ratings and price targets for Kadmon and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Risk and Volatility
Kadmon has a beta of 2.58, suggesting that its share price is 158% more volatile than the S&P 500. Comparatively, Kadmon’s peers have a beta of 1.03, suggesting that their average share price is 3% more volatile than the S&P 500.
This table compares Kadmon and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation & Earnings
This table compares Kadmon and its peers revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Kadmon||$26.06 million||-$208.75 million||-2.08|
|Kadmon Competitors||$564.12 million||$96.17 million||44.40|
Kadmon’s peers have higher revenue and earnings than Kadmon. Kadmon is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Institutional and Insider Ownership
51.9% of Kadmon shares are held by institutional investors. Comparatively, 43.5% of shares of all “Biopharmaceuticals” companies are held by institutional investors. 8.4% of Kadmon shares are held by company insiders. Comparatively, 15.3% of shares of all “Biopharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Kadmon peers beat Kadmon on 7 of the 12 factors compared.
Kadmon Company Profile
Kadmon Holdings, Inc. is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases. Its product pipeline consists of KD025, Tesevatinib and KD034. The Company’s other products include Ribasphere RibaPak, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir. KD025 is an orally available, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a molecular target in multiple autoimmune, fibrotic and neurodegenerative diseases. Tesevatinib is an oral tyrosine kinase inhibitor (TKI) designed to block key molecular drivers of tumor growth, metastases and drug resistance. KD034 is the Company’s portfolio of enhanced formulations of trientine hydrochloride for the treatment of Wilson’s disease.
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.